Companies / CUV

CLINUVEL PHARMACEUTICALS LIMITED

ASX:CUVPharmaceuticals, Biotechnology & Life Sciences
50.4M shares on issueASX (delayed) · as of 28 July 2026$9.81price · delayed$507.3Mmarket cap · indicative
A
Dilution grade

No major dilution pressure signals in current disclosures

Cash runwayno data — no longer lodges quarterly cash reports (4C/5B)
Share-count growth (24m)0.6%
Raise cadence (24m)0 cash raises
Options & rights overhang0.3% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

CLINUVEL PHARMACEUTICALS LIMITED's ordinary share count was 50M as of April 2026, up 0.6% since April 2025. The company did not raise capital in the past 24 months. Options and rights on issue could convert into 172,292 new shares, equal to 0.3% of the current share count, with 0% in the money. The company no longer lodges quarterly cash reports, so no quarterly cash balance or funding-runway figure applies. No proposed securities issues (Appendix 3B) are currently pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
0.3%
Max option dilution
0.0%
ITM option dilution
0
Raises · last 12 months
—
Cash cover · stale filings

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 50.4M per ASX (delayed) (28 July 2026).
50.1M50.2M50.4MDec 24Sept 25July 26

Cash runway

—
stale Last quarterly cash report is more than 12 months old (quarter ended 31 Dec 2022) — runway is not computed from stale filings.
$189.0M available cash reported at 31 Dec 2022.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Dec 2022.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
26 July 20263H · cancellationCUV : ORDINARY FULLY PAID50.4MAppendix 3H
7 May 20263G · unquotedORDINARY FULLY PAID50.4MAppendix 3G
16 Apr 20263H · cancellationCUV : ORDINARY FULLY PAID50.4MAppendix 3H
12 Apr 20262A · quoted issueCUV : ORDINARY FULLY PAID50.4MAppendix 2A
1 Jan 20263H · cancellationCUV : ORDINARY FULLY PAID50.2MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

No equity raises in the last 24 months.
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

0.3%
Total overhang · of current shares
0.0%
In the money · at current price
172k
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
3 Sept 2024Karen AgersborgBuy8k—$128k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026$PUpdate - SCENESSE in vitiligo
26 July 2026Notification of cessation of securities - CUV
22 July 2026$PCLINUVEL strategic reorganisation to refocus on U.S. markets
20 July 2026CLINUVEL's ADS commences trading on Nasdaq
19 July 2026CLINUVEL's ADS to commence trading on Nasdaq
12 July 2026$PSCENESSE approved for EPP in Canada
2 July 2026CLINUVEL confirms terms of CEO's Employment Agreement
15 June 2026$PCLINUVEL publicly files 20-F to U.S. SEC
1 June 2026CLINUVEL US Non-Deal Roadshow Presentation
7 May 2026Notification regarding unquoted securities - CUV
27 Apr 2026$PCLINUVEL update on Level II ADR upgrade, Nasdaq uplist
26 Apr 2026$PFDA relaxes SCENESSE postmarketing requirement
23 Apr 2026$PFinal EMA scientific advice for pivotal Phase III vitiligo
16 Apr 2026Notification of cessation of securities - CUV
12 Apr 2026Section 708A Cleansing Statement
12 Apr 2026Application for quotation of securities - CUV
12 Apr 2026Change in substantial holding
2 Apr 2026CLINUVEL reports highlights from AAD 2026
26 Mar 2026$PCLINUVEL's global programs showcased at AAD
19 Mar 2026$PChair Letter to Shareholders

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.